Concurrent gene editing and reprogramming of sickle cell disease fibroblasts using dual measles virus vectors
Grant Project Details:
Awardee:
Patricia Devaux, PhD
Timeframe:
2020-2022
Location:
Mayo Clinic | Rochester, MN
Amount:
$249,998
Status:
In Process
Explore all RMM grants awarded since inception
Grant Description
We have developed a new technology to reprogram human cells to go back to a state from which they can then develop into other kinds of cells. Our technology is based on a strain of Measles virus, one of the safest vaccines in human history. In this project we will use modify our technology to correct genetic mutation in the human genome and particularly in patients with inherited red blood cell disorders, such as sickle cell disease.